C
지놈앤컴퍼니
314130KOSDAQ49.0 / 100
Reference Date: 2026-10-23
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 18.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Genom and Company aims to grow into a fully integrated pharmaceutical company by focusing on innovative drug development, utilizing its GNOCLE™ platform to advance pipeline candidates such as the immunotherapy GENA-104 and microbiome-based treatment GEN-001. The company also diversifies its business through CDMO services and its microbiome cosmetics brand 'UIQ'.
Number of Employees
96people
Average Salary
60.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.82Industry Average 1.201.0Point
1.5x industry avg (risky)
ROE
-7.20Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
6.62Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲41.3% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲17.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -23.6% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (18%, downtrend)
Current 3,995Won52-week high 9,97052-week low 2,660
1-month return6.0Point
1m +18.37% (strong rise)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
4 totalPositive 0Neutral 4Negative 0
- Neutral전환가액의조정2026-10-13
- Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-10-07
- Neutral기타경영사항(자율공시) (전환우선주의 보통주 전환청구)2026-10-07
- Neutral기업설명회(IR)개최2026-09-29